319 related articles for article (PubMed ID: 10807034)
1. Development of a novel class of monocyclic and bicyclic alkyl amides that exhibit CB1 and CB2 cannabinoid receptor affinity and receptor activation.
Berglund BA; Fleming PR; Rice KC; Shim JY; Welsh WJ; Howlett AC
Drug Des Discov; 2000; 16(4):281-94. PubMed ID: 10807034
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Showalter VM; Compton DR; Martin BR; Abood ME
J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'.
Papahatjis DP; Nikas SP; Kourouli T; Chari R; Xu W; Pertwee RG; Makriyannis A
J Med Chem; 2003 Jul; 46(15):3221-9. PubMed ID: 12852753
[TBL] [Abstract][Full Text] [Related]
5. The CB1 cannabinoid receptor in the brain.
Howlett AC
Neurobiol Dis; 1998 Dec; 5(6 Pt B):405-16. PubMed ID: 9974174
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols.
Papahatjis DP; Kourouli T; Abadji V; Goutopoulos A; Makriyannis A
J Med Chem; 1998 Mar; 41(7):1195-200. PubMed ID: 9544219
[TBL] [Abstract][Full Text] [Related]
7. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
Rhee MH; Vogel Z; Barg J; Bayewitch M; Levy R; Hanus L; Breuer A; Mechoulam R
J Med Chem; 1997 Sep; 40(20):3228-33. PubMed ID: 9379442
[TBL] [Abstract][Full Text] [Related]
8. Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs.
Busch-Petersen J; Hill WA; Fan P; Khanolkar A; Xie XQ; Tius MA; Makriyannis A
J Med Chem; 1996 Sep; 39(19):3790-6. PubMed ID: 8809166
[TBL] [Abstract][Full Text] [Related]
9. The neurobiology and evolution of cannabinoid signalling.
Elphick MR; Egertová M
Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs.
Melvin LS; Milne GM; Johnson MR; Subramaniam B; Wilken GH; Howlett AC
Mol Pharmacol; 1993 Nov; 44(5):1008-15. PubMed ID: 8246904
[TBL] [Abstract][Full Text] [Related]
11. Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview.
Basavarajappa BS; Hungund BL
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):287-99. PubMed ID: 12052043
[TBL] [Abstract][Full Text] [Related]
12. SR144528 as inverse agonist of CB2 cannabinoid receptor.
Rhee MH; Kim SK
J Vet Sci; 2002 Sep; 3(3):179-84. PubMed ID: 12514329
[TBL] [Abstract][Full Text] [Related]
13. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
Durdagi S; Kapou A; Kourouli T; Andreou T; Nikas SP; Nahmias VR; Papahatjis DP; Papadopoulos MG; Mavromoustakos T
J Med Chem; 2007 Jun; 50(12):2875-85. PubMed ID: 17521177
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid.
Pinto JC; Potié F; Rice KC; Boring D; Johnson MR; Evans DM; Wilken GH; Cantrell CH; Howlett AC
Mol Pharmacol; 1994 Sep; 46(3):516-22. PubMed ID: 7935333
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity.
Melvin LS; Milne GM; Johnson MR; Wilken GH; Howlett AC
Drug Des Discov; 1995 Nov; 13(2):155-66. PubMed ID: 8872458
[TBL] [Abstract][Full Text] [Related]
17. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
[TBL] [Abstract][Full Text] [Related]
18. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling.
Tao Q; Abood ME
J Pharmacol Exp Ther; 1998 May; 285(2):651-8. PubMed ID: 9580609
[TBL] [Abstract][Full Text] [Related]
19. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model.
Howlett AC; Johnson MR; Melvin LS; Milne GM
Mol Pharmacol; 1988 Mar; 33(3):297-302. PubMed ID: 3352594
[TBL] [Abstract][Full Text] [Related]
20. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
Stern E; Muccioli GG; Millet R; Goossens JF; Farce A; Chavatte P; Poupaert JH; Lambert DM; Depreux P; Hénichart JP
J Med Chem; 2006 Jan; 49(1):70-9. PubMed ID: 16392793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
